S&P Futures
4,292.25 +15.50 (+0.36%) Dow Futures
34,055.00 +92.00 (+0.27%) Nasdaq Futures
13,555.75 +62.50 (+0.46%) Russell 2000 Futures
1,999.30 +10.20 (+0.51%) Crude Oil
89.30 +1.19 (+1.35%) Gold
1,785.20 +8.50 (+0.48%)
Trevi Therapeutics, Inc. (TRVI)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 3.7000 |
| Open | 3.8000 |
| Bid | 3.7800 x 800 |
| Ask | 4.4500 x 800 |
| Day's Range | 3.5200 - 3.8250 |
| 52 Week Range | 0.4600 - 4.6830 |
| Volume | |
| Avg. Volume | 1,480,037 |
| Market Cap | 97.7M |
| Beta (5Y Monthly) | 0.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7560 |
| Earnings Date | Mar 23, 2022 - Mar 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
- PR Newswire
Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced financial results for the quarter ended June 30, 2022, as well as provided business updates.
- PR Newswire
Trevi Therapeutics to Present at Upcoming August Conferences
Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced it will be presenting at the following investor and medical meeting conferences:
- PR Newswire
Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced that management will host a conference call and live audio webcast on Thursday, August 11, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the second quarter ended June 30
